Better Artificial Intelligence Stock for 2026: BigBear.ai vs. Cerebras Systems

Cerebras Systems is the article’s preferred AI investment, with FY2025 revenue up 75.7% to $510.0 million and net income of $237.8 million, while second-quarter sales rose 74% to $180.1 million. Its shares carry a 47.7x price-to-sales ratio and 217.4x forward P/E, and free cash flow was negative $392.8 million. BigBear.ai reported FY2025 revenue down 19.3% to $127.7 million and a $293.9 million net loss, alongside a class action lawsuit and financial-statement restatements; its second-quarter revenue later grew 13% year over year to $36.7 million, attributed to its Ask Sage acquisition.

Analysis

The key distinction is not software versus hardware, but execution risk versus duration risk. BBAI’s weak revenue base and reported control/restatement issues make any rebound hard to underwrite until organic growth is separated from acquired revenue; federal exposure also leaves results sensitive to procurement timing and budget execution. Its balance-sheet liquidity may limit near-term financing pressure, but does not resolve the credibility discount. The risk is that a small company can still be expensive at 8x sales if growth is acquisition-led and cash burn persists.

CBRS has stronger reported momentum, but the gap between reported net income and deeply negative free cash flow matters more than headline profitability: investors should establish whether cash use reflects growth investment, working-capital timing, or recurring economics before extrapolating earnings. At 47.7x sales, even a modest slowdown or customer concentration surprise can compress the multiple sharply. Amazon is both a potential demand/validation channel and a substitute risk through internal chip development; partnership details, revenue contribution, and renewal terms are not provided and should not be assumed.

Near term, valuation and earnings-quality scrutiny are likely to dominate. Over 1–3 months, watch BBAI organic growth excluding Ask Sage and cash burn, and CBRS bookings/backlog, customer concentration, gross margins, and conversion of earnings to cash. Over 6–18 months, the central question for CBRS is whether its architecture can sustain differentiated utilization as incumbent and in-house accelerators improve. The contrarian point: CBRS’s growth may justify a premium, but not necessarily this premium; BBAI’s low relative multiple is not evidence of cheapness when governance and organic demand remain unresolved.

Key Decisions for Investors

• Prefer a watchlist position in CBRS over BBAI, not an automatic momentum chase. Add only after verifying repeat-customer demand and cash-flow conversion; reduce if growth decelerates materially or operating cash use keeps widening without corresponding backlog/utilization evidence.
• Underweight BBAI pending evidence that growth is organic and reporting controls are remediated. Reassess if subsequent filings show sustained revenue growth excluding Ask Sage, improving free cash flow, and resolution of the restatement/class-action overhang.
• Potential relative-value expression: a small, risk-capped CBRS/BBAI pair (long CBRS, short BBAI) captures relative execution quality, but size against CBRS’s substantial valuation and cash-flow risk; avoid treating the pair as market-neutral without checking beta and borrow availability.
• Key falsifiers: BBAI’s organic revenue and cash burn improve sustainably, or CBRS reports weaker bookings, customer concentration, margin deterioration, or no credible path from accounting earnings to cash generation. Verify Amazon partnership economics before assigning CBRS incremental value.